Biotech firm Amyris, Inc. (NASDAQ: AMRS) and ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, have concluded their joint venture (JV) agreement to support the commercialization of a next-generation COVID-19 vaccine.  Following the news, shares of Amyris rose 8.3% to close at $5.86 on Monday, while shares of ImmunityBio had jumped 24% at the close.  Background  Amyris and ImmunityBio will combine their vaccine technology with their manufacturing capabilities. Notably, upon completion of successful human trials and regulatory approval, the joint venture aims to deliver the second-generation vaccine in 2022 to underserved parts of the world, where cost and supply-chain limitations have made access to current vaccine technology challenging.
https://www.tipranks.com/news/amyris-shares-jump?utm_source=advfn.com&utm_medium=referral
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more Amyris Charts.
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Amyris Charts.